GENE ONLINE|News &
Opinion
Blog

Obesity
Trending PfizerGLP-1
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns
2025-04-15
News Flash Obesity
Study Finds Married Men Three Times More Likely to Be Obese Than Single Men
2025-03-14
News Flash Insulin
Brief Junk Food Intake Impairs Brain’s Insulin Response, Study Finds
2025-03-01
News Flash food safety policies.
Alarm Raised Over Ultra-Processed Foods Dominating Baby and Toddler Market
2025-02-27
Trending ZepboundEli Lilly
Lilly Slashes Zepbound Vial Prices by Up to 50% to Expand Access for Uninsured Patients
2025-02-26
Trials & Approvals ObesityClinical Trial
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Trials & Approvals Obstructive Sleep Apnea
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
Trending ObesityWeight loss
The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas
2024-11-01
In-Depth Weight lossmarket insights
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
Special AwardsTang Prize
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Trending Weight loss
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
Editors' Picks LiraglutideObesitySemaglutideTirzepatide
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)
2024-03-07
Editors' Picks ObesityEli LillyNovo NordiskTirzepatideSemaglutideLiraglutideNaltrexonebupropion
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (First Part)
2024-02-15
M&A ObesityNovo NordiskCatalent
Novo Nordisk Acquire Catalent for $16.5 Billion, Enhancing Obesity Drugs Production Capacity
2024-02-07
R&D Semaglutide
Semaglutide-Based Medications, Ozempic and Wegovy, Show Lower Suicidal Ideation Risk
2024-01-17
1 2 3
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
READ MORE
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top